Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study

Defining the “Frequent Exacerbator” Phenotype in COPD

(2018) Olivier Le Rouzic et al.   CHEST

The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients

(2018) Xingxing He et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Fibroblast growth factor 23 and Klotho contribute to airway inflammation

(2018) Stefanie Krick et al.   EUROPEAN RESPIRATORY JOURNAL

Longitudinal FGF23 Trajectories and Mortality in Patients with CKD

(2017) Tamara Isakova et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease

(2017) Jair Munoz Mendoza et al.   KIDNEY INTERNATIONAL

Clinical and Functional Lung Parameters Associated With Frequent Exacerbator Phenotype in Subjects With Severe COPD

(2017) Alberto Capozzolo et al.   Respiratory Care

Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization

(2017) Asli Gorek Dilektasli et al.   International Journal of Chronic Obstructive Pulmonary Disease

Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study

(2017) Mette Reilev et al.   npj Primary Care Respiratory Medicine

Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia

(2017) Stefanie Krick et al.   Scientific Reports

Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization

(2016) Shennin N. Yuen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease

(2016) Saurav Singh et al.   KIDNEY INTERNATIONAL

Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes

(2016) Xiang Hu et al.   Scientific Reports

Klotho expression is reduced in COPD airway epithelial cells: effects on inflammation and oxidant injury

(2015) W. Gao et al.   CLINICAL SCIENCE

Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure

(2015) Ingrid A. Andersen et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population

(2015) Lorcan McGarvey et al.   RESPIRATORY MEDICINE

Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial

(2014) Sevim Uzun et al.   Lancet Respiratory Medicine

Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease

(2013) Jadwiga A Wedzicha et al.   BMC Medicine

Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype

(2013) Jadwiga A. Wedzicha et al.   CHEST

Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes

(2013) David E. Leaf et al.   CLINICAL ENDOCRINOLOGY

Iron and Obesity Status-Associated Insulin Resistance Influence Circulating Fibroblast-Growth Factor-23 Concentrations

(2013) José Manuel Fernández-Real et al.   PLoS One

Update on fibroblast growth factor 23 in chronic kidney disease

(2012) Myles Wolf   KIDNEY INTERNATIONAL

Fibroblast Growth Factor-23 and Hypophosphatemia in Chronic Obstructive Pulmonary Disease Patients

(2011) Mohamed Elsammak et al.   Journal of Medical Biochemistry

Changes in Forced Expiratory Volume in 1 Second over Time in COPD

(2011) Jørgen Vestbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis

(2011) Andrew P. Yu et al.   JOURNAL OF MEDICAL ECONOMICS

Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype

(2010) Hua Li et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Circulating Fibroblast Growth Factor-23 Is Associated With Fat Mass and Dyslipidemia in Two Independent Cohorts of Elderly Individuals

(2010) Majd A.I. Mirza et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease

(2010) Marjolein Brusse-Keizer et al.   Clinical Respiratory Journal

COPD Recent Findings: Impact on Clinical Practice

(2010) Annabelle Couillard et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

(2010) John R. Hurst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active

(2009) Takashi Shimada et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

(2008) Orlando M. Gutiérrez et al.   NEW ENGLAND JOURNAL OF MEDICINE